Kiniksa Pharmaceuticals Ltd Cash Flow Conversion Efficiency
Kiniksa Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has a cash flow conversion efficiency ratio of 0.073x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.46 Million) by net assets ($654.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kiniksa Pharmaceuticals Ltd (2016–2025)
Cash flow conversion efficiency of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. This chart illustrates how Kiniksa Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Kiniksa Pharmaceuticals Ltd for real-time trading data and today's change.
Kiniksa Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained
Kiniksa Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kiniksa Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see Kiniksa Pharmaceuticals Ltd (KNSA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pampa Energia SA ADR
NYSE:PAM
|
0.053x |
|
Beta Technologies, Inc.
NYSE:BETA
|
-0.055x |
|
Max Financial Services Limited
NSE:MFSL
|
0.263x |
|
Ningbo Orient Wires and Cables Co Ltd
SHG:603606
|
0.194x |
|
Wacker Chemie AG
XETRA:WCH
|
0.028x |
|
BIDVEST SP.ADR/2 RC-05
F:NQL
|
N/A |
|
RioCan Real Estate Investment Trust
TO:REI-UN
|
0.024x |
|
Ufp Industries Inc
NASDAQ:UFPI
|
0.054x |
Annual Cash Flow Conversion Efficiency for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. Review Kiniksa Pharmaceuticals Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $567.61 Million | $25.69 Million | 0.045x | -22.76% |
| 2024-12-31 | $438.44 Million | $25.69 Million | 0.059x | +93.31% |
| 2023-12-31 | $438.84 Million | $13.30 Million | 0.030x | +106.77% |
| 2022-12-31 | $396.15 Million | $5.81 Million | 0.015x | +102.15% |
| 2021-12-31 | $185.04 Million | $-126.30 Million | -0.683x | -55.94% |
| 2020-12-31 | $311.94 Million | $-136.53 Million | -0.438x | +37.70% |
| 2019-12-31 | $225.42 Million | $-158.37 Million | -0.703x | -142.18% |
| 2018-12-31 | $279.27 Million | $-81.01 Million | -0.290x | -151.82% |
| 2017-12-31 | $-89.71 Million | $-50.22 Million | 0.560x | -34.12% |
| 2016-12-31 | $-25.73 Million | $-21.87 Million | 0.850x | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more